Back
Brainstorm Cell Therapeutics Stock Price Chart
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
29
BCLI
Brainstorm Cell Therapeutics
Last Price:
$1.18
Seasonality Move:
53.36%
7 Day Trial
ALL ACCESS PASS
$
7
-
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BCLI is experiencing slight buying pressure.
Brainstorm Cell Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.22 | Sell |
| 20-day SMA: | 1.18 | Sell |
| 50-day SMA: | 1.18 | Sell |
| 200-day SMA: | 1.57 | Sell |
| 8-day EMA: | 1.19 | Sell |
| 20-day EMA: | 1.19 | Sell |
| 50-day EMA: | 1.19 | Sell |
| 200-day EMA: | 2.22 | Sell |
Brainstorm Cell Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.01 | Buy |
| Relative Strength Index (14 RSI): | 48.72 | Sell |
| Chaikin Money Flow: | 145046 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | ( - ) | Buy |
| Bollinger Bands (100): | ( - ) | Buy |
Brainstorm Cell Therapeutics Technical Analysis
| Jul 3 | Jul 7 | Jul 8 | Jul 9 | Jul 10 | Jul 11 | Jul 14 | Jul 15 | Jul 16 | Jul 17 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul | ||||||||||
| 03 | 07 | 08 | 09 | 10 | 11 | 14 | 15 | 16 | 17 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Brainstorm Cell Therapeutics Stock
Is Brainstorm Cell Therapeutics Stock a Buy?
-
Brainstorm Cell Therapeutics share price is 1.17 while BCLI 8-day simple moving average is 1.22, which is a Sell signal.
-
The stock price of BCLI is 1.17 while Brainstorm Cell Therapeutics 20-day SMA is 1.18, which makes it a Sell.
-
Brainstorm Cell Therapeutics 50-day simple moving average is 1.18 while BCLI share price is 1.17, making it a Sell technically.
-
BCLI stock price is 1.17 and Brainstorm Cell Therapeutics 200-day simple moving average is 1.57, creating a Sell signal.
BCLI Technical Analysis vs Fundamental Analysis
Sell
29
Brainstorm Cell Therapeutics (BCLI)
is a Sell
Is Brainstorm Cell Therapeutics a Buy or a Sell?
-
Brainstorm Cell Therapeutics stock is rated a SellThe current Brainstorm Cell Therapeutics [BCLI] share price is $1.17. The Score for BCLI is 29, which is 42% below its historic median score of 50, and infers higher risk than normal.
Brainstorm Cell Therapeutics Stock Info
Market Cap:
9.3M
Price in USD:
1.17
Share Volume:
1.2M
Brainstorm Cell Therapeutics 52-Week Range
52-Week High:
6.00
52-Week Low:
0.72
Sell
29
Brainstorm Cell Therapeutics (BCLI)
is a Sell
Brainstorm Cell Therapeutics Share Price Forecast
-
What is the Brainstorm Cell Therapeutics stock price today?The Brainstorm Cell Therapeutics stock price is 1.17 USD today.
-
Will BCLI stock go up or go down?Brainstorm Cell Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Brainstorm Cell Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Brainstorm Cell Therapeutics is overvalued.
Is Brainstorm Cell Therapeutics Stock a Buy?
-
Brainstorm Cell Therapeutics share price is 1.17 while BCLI 8-day exponential moving average is 1.19, which is a Sell signal.
-
The stock price of BCLI is 1.17 while Brainstorm Cell Therapeutics 20-day EMA is 1.19, which makes it a Sell.
-
Brainstorm Cell Therapeutics 50-day exponential moving average is 1.19 while BCLI share price is 1.17, making it a Sell technically.
-
BCLI stock price is 1.17 and Brainstorm Cell Therapeutics 200-day simple moving average is 2.22, creating a Sell signal.
Fundamental Analysis of Brainstorm Cell Therapeutics
Is Brainstorm Cell Therapeutics a good investment?
-
Analysts estimate an earnings increase this quarter of $0.23 per share, an increase next quarter of $0.23 per share, an increase this year of $0.50 per share, and an increase next year of $0.16 per share.
Technical Analysis of Brainstorm Cell Therapeutics
Should I short Brainstorm Cell Therapeutics stock?
-
BCLI Moving Average Covergence Divergence (MACD) indicator is 0.01, suggesting Brainstorm Cell Therapeutics is a Buy
-
Brainstorm Cell Therapeutics Relative Strength Index (RSI) is 48.72, which suggest Brainstorm Cell Therapeutics is oversold
-
The Bollinger Bands (25) for Brainstorm Cell Therapeutics is ( - ), which suggest Brainstorm Cell Therapeutics is a Buy
-
The Bollinger Bands (100) for Brainstorm Cell Therapeutics is ( - ), which suggest Brainstorm Cell Therapeutics is a Buy
* Brainstorm Cell Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.